Lineage Cell Therapeutics (LCTX) Operating Expenses (2010 - 2026)

Lineage Cell Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $9.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 16.37% year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at $52.5 million (up 69.97% YoY), and the FY2025 full-year result was $51.2 million, up 65.2% from the prior year.
• Operating Expenses for Q1 2026 stood at $9.3 million, down from $13.2 million in the prior quarter.
• The five-year high for Operating Expenses was $22.5 million in Q2 2025, with the low at $7.3 million in Q2 2024.
• Historically, Operating Expenses has averaged $9.5 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses plunged 71.06% — and 2025, when it surged 209.9%.
• Lineage Cell Therapeutics' Operating Expenses stood at $8.5 million in 2022, then dropped by 3.05% to $8.2 million in 2023, then retreated by 2.64% to $8.0 million in 2024, then soared by 64.9% to $13.2 million in 2025, then declined by 29.17% to $9.3 million in 2026.
• The last three Operating Expenses figures came in at $9.3 million (Q1 2026), $13.2 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.